Citations

Mayo Clinic

Clear

1291 citation(s) found for "Wu, Erik".

0660 Higher Amounts of REM Sleep without Atonia Predict Phenoconversion To Defined Neurodegenerative Disorders in Idiopathic REM Sleep Behavior Disorder
McCarter, SJ, Feemster, John, McCarter, Allison R., Sandness, D., Timm, P C, Teigen, Luke, Silber, Michael H. , Louis, Erik K. St. , St Louis, E K , Boeve, Bradley F.

Sleep | April 27, 2018 | Volume: 41 | Issue: suppl_1 | Pages: A245-A245

10.1093/sleep/zsy061.659 Get It

0682 A Novel, Highly Efficient REM Sleep without Atonia Visual Analysis Method for REM Sleep Behavior Disorder Diagnosis
Feemster, John, Timm, P C, Teigen, Luke, Louis, Erik K. St. , St Louis, E K , McCarter, Stuart J.

Sleep | April 27, 2018 | Volume: 41 | Issue: suppl_1 | Pages: A253-A253

10.1093/sleep/zsy061.681 Get It

1021 Cognitive, Motor, and Autonomic Function Impairments in Idiopathic REM Sleep Behavior Disorder
Teigen, Luke, Boeve, Angelica, Feemster, John, Timm, Paul, Sandness, D., Duwell, E J, Commers, N, McCord, Siri V., Junna, Mithri R. , Tippmann‐Peikert, Maja, Silber, Michael H. , Louis, Erik K. St. , St Louis, E K , Duwell, Ethan J. , McCarter, Stuart J. , Lipford, Melissa C. , Boeve, Bradley F.

Sleep | April 27, 2018 | Volume: 41 | Issue: suppl_1 | Pages: A379-A379

10.1093/sleep/zsy061.1020 Get It

Streamlining cardiopulmonary exercise testing for use as a screening and tracking tool in primary care
Kim, Chul‐Ho , Iterson, Erik H. Van , Hansen, James E. , MacCarter, Dean, Johnson, Bruce D. , MacCarter, Dean J, Van Iterson, Erik H

Pulmonary Circulation | April 25, 2018 | Volume: 8 | Issue: 2 | Pages: 1-8

10.1177/2045894018776489 | PMID 29693481 Get It

Cardiopulmonary exercise testing (CPET) using a spectrum of different approaches demonstrates usefulness for objectively assessing patient disease severity in clinical and research settings. Still, an absence of trained specialists and/or improper data interpretation techniques can pose major limitations to the effective use of CPET for the clinical classification of patients. This study aimed to test an automated disease likelihood scoring algorithm system based on cardiopulmonary responses during a simplified step‐test protocol. For patients with heart failure (HF), pulmonary hypertension (PAH), obstructive lung disease (OLD), or restrictive lung disease (RLD), we compared patient scores stratified into one of four “silos” generated from our novel algorithm system against patient evaluations provided by expert clinicians. Patients with HF (n = 12), PAH (n = 9), OLD (n = 16), or RLD (n = 10) performed baseline pulmonary function testing followed by submaximal step‐testing. Breath‐by‐breath measures of ventilation and gas exchange, in addition to oxygen saturation and heart rate were collected continuously throughout testing. The algorithm demonstrated close alignment with patient assessments provided by clinical specialists: HF (r = 0.89, P < 0.01); PAH (r = 0.88, P < 0.01); OLD (r = 0.70, P < 0.01); and RLD (r = 0.88, P < 0.01). Furthermore, the algorithm was capable of differentiating major disease from other disease pathologies. Thus, in a clinically relevant manner, these data suggest this simplified automated disease algorithm scoring system used during step‐testing to identify the likelihood that patients have HF, PAH, OLD, or RLD closely correlates with patient assessments conducted by trained clinicians.
External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
Cheung, Angela , Gulamhusein, Aliya , Juran, Brian D., Schlicht, Erik M., McCauley, Bryan M. , Atkinson, Elizabeth J. , Cheung, Angela C, de Andrade, Mariza, Lazaridis, Konstantinos N. , Andrade, Mariza de

Hepatology Communications | April 24, 2018 | Volume: 2 | Issue: 6 | Pages: 676-682

10.1002/hep4.1186 | PMID 29881819 Get It

The United Kingdom‐Primary Biliary Cholangitis (UK‐PBC) risk scores are a set of prognostic models that estimate the risk of end‐stage liver disease in patients with PBC at 5‐, 10‐ and 15‐year intervals. They have not been externally validated outside the United Kingdom. In this retrospective, external validation study, data were abstracted from outpatient charts and discrimination and calibration of the UK‐PBC risk scores were assessed. A total of 464 patients with PBC treated with ursodeoxycholic acid were included. The median diagnosis age was 52.4 years, and 88% were female patients. The cumulative incidence of events was 6%, 9%, and 15% at 5, 10, and 15 years, respectively. Concordance (c‐statistic) was 0.88, 0.85, and 0.84 using the 5‐, 10‐ and 15‐year risk scores, respectively, which was slightly lower than values observed in the United Kingdom validation cohort. Using the 5‐year risk score, more events were observed than predicted (25 versus 16.8; P = 0.046); using the 10‐year risk score, there was no difference between the observed and predicted number of events (35 versus 44.9; P = 0.14); conversely, using the 15‐year risk score, fewer events were observed than predicted (46 versus 67.5; P = 0.009). Limiting evaluation by the 15‐year UK‐PBC risk score to those with >10 years of follow‐up demonstrated no difference between observed and predicted events. Using the 5‐year risk score, patients within the highest quartile had statistically significant worse event‐free survival compared to the rest of the cohort: 82% versus 98% at 5 years, 73% versus 97% at 10 years, and 58% versus 93% at 15 years. Conclusion: In patients assessed at a North American tertiary medical center, the UK‐PBC risk score had excellent discrimination and was reasonably calibrated both in the short and long term. (Hepatology Communications 2018;2:676‐682)
Resistive and elastic work of breathing in older and younger adults during exercise
Smith, Joshua R. , Cross, Troy J. , Iterson, Erik H. Van , Johnson, Bruce D. , Olson, Thomas P. , Van Iterson, Erik H , Smith, Joshua R , Cross, Troy James

Journal of Applied Physiology | April 19, 2018 | Volume: 125 | Issue: 1 | Pages: 190-197

10.1152/japplphysiol.01105.2017 | PMID 29672228 Get It

It is unknown whether the greater total work of breathing (WOB) with aging is due to greater elastic and/or resistive WOB. We hypothesized that older compared with younger adults would exhibit a greater total WOB at matched ventilations (V̇e) during graded exercise, secondary to greater inspiratory resistive and elastic as well as expiratory resistive WOB. Older (OA: 60 ± 8 yr; n = 9) and younger (YA: 38 ± 7 yr; n = 9) adults performed an incremental cycling test to volitional fatigue. Esophageal pressure, inspiratory (IRV) and expiratory reserve volumes (ERV), expiratory flow limitation (EFL), and ventilatory variables were measured at matched V̇e (i.e., 25, 50, and 75 l/min) during exercise. The inspiratory resistive and elastic as well as expiratory resistive WOB were quantified using the Otis method. At V̇e of 75 l/min, older adults had greater %EFL and larger tidal volumes to inspiratory capacity but smaller relative IRV ( P ≤ 0.03) than younger adults. Older compared with younger adults had greater total WOB at V̇Eof 50 and 75 l/min (OA: 90 ± 43 vs. YA: 49 ± 21 J/min; P < 0.04 for both). At V̇e of 75 l/min, older adults had greater inspiratory elastic and resistive WOB (OA: 44 ± 27 vs. YA: 24 ± 22 and OA: 23 ± 15 vs. YA: 11 ± 3 J/min, respectively, P < 0.03 for both) and expiratory resistive WOB (OA: 23 ± 19 vs. YA: 14 ± 9 J/min, P = 0.02) than younger adults. These data demonstrate that aging-induced pulmonary alterations result in greater inspiratory elastic and resistive as well as expiratory resistive WOB, which may have implications for the integrated response during exercise.NEW & NOTEWORTHY Aging-induced changes to the pulmonary system result in increased work of breathing (WOB) during exercise. However, it is not known whether this higher WOB with aging is due to differences in elastic and/or resistive WOB. Herein, we demonstrate that older adults exhibited greater inspiratory elastic and resistive as well as expiratory resistive WOB during exercise.
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection
Lee, Christine H. , Orenstein, Robert , Khanna, Sahil , Hecht, Gail , Gerding, Dale N. , Dubberke, Erik R.

Clinical Infectious Diseases | March 28, 2018 | Volume: 67 | Issue: 8 | Pages: 1198-1204

10.1093/cid/ciy259 | PMID 29617739 Get It

Exercise on‐transition uncoupling of ventilatory, gas exchange and cardiac hemodynamic kinetics accompany pulmonary oxygen stores depletion to impact exercise intolerance in human heart failure
Iterson, Erik H. Van , Smith, Joshua R. , Olson, Thomas P. , Van Iterson, Erik H , Smith, Joshua R

Acta Physiologica | March 25, 2018 | Volume: 223 | Issue: 4 | Pages: No page available

10.1111/apha.13063 | PMID 29575588 Get It

AbstractAimIn contrast to knowledge that heart failure (HF) patients demonstrate peak exercise uncoupling across ventilation, gas exchange and cardiac haemodynamics, whether this dyssynchrony follows that at the exercise on‐transition is unclear. This study tested whether exercise on‐transition temporal lag for ventilation relative to gas exchange and oxygen pulse (O2pulse) couples with effects from abnormal pulmonary gaseous oxygen store (O2store) contributions to O2 to interdependently precipitate persistently elevated ventilatory demand and low oxidative metabolic capacity in HF.MethodsBeat‐to‐beat HR and breath‐to‐breath ventilation and gas exchange were continuously acquired in HF (N = 9, ejection fraction = 30 ± 9%) and matched controls (N = 10) during square‐wave ergometry at 60% O2peak (46 ± 14 vs 125 ± 54‐W, P < .001). Temporal responses across E, O2 and O2pulse were assessed for the exercise on‐transition using single exponential model Phase II on‐kinetic time constants (τ = time to reach 63% steady‐state rise). Breath‐to‐breath gas fractions and respiratory flows were used to determine O2stores.ResultsHF vs controls: τ for E (137 ± 93 vs 74 ± 40‐seconds, P = .03), O2 (60 ± 40 vs 23 ± 5‐seconds, P = .03) and O2pulse (28 ± 18 vs 23 ± 15‐seconds, P = .59). Within HF, τ for E differed from O2pulse (P < .02), but not O2. Exercise E rise (workload indexed) differed in HF vs controls (545 ± 139 vs 309 ± 88‐mL min−1 W−1, P < .001). Exercise on‐transition O2store depletion in HF exceeded controls, generally persisting to end‐exercise.ConclusionThese data suggest HF demonstrated exercise on‐transition O2store depletion (high O2store contribution to O2) coupled with dyssynchronous E, O2 and O2pulse kinetics—not attributable to prolonged cardiac haemodynamics. Persistent high ventilatory demand and low oxidative metabolic capacity in HF may be precipitated by physiological uncoupling occurring within the exercise on‐transition.
A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia
Chen, Xu , Gustafsson, Stefan , Whitington, Thomas, Borné, Yan , Lorentzen, Erik , Sun, Jitong , Almgren, Peter , Su, Jun , Lu, Yi , Zhan, Yiqiang , Hägg, Sara , Svensson, Per , Smedby, Karin E. , Lindgren, Cecilia M. , Morris, Andrew P. , Melander, Olle , Karlsson, Thomas , Fairé, Ulf dé , Lind, Lars , Pedersen, Nancy L. , Magnusson, Patrik K. E. , Lu, Yi , Karlsson, Robert , Song, Jie , Slager, Susan L. , Ingelsson, Erik , Caidahl, Kenneth , Engström, Gunnar , Karlsson, Mikael C. I. , Frostegård, Johan

Human Molecular Genetics | March 14, 2018 | Volume: 27 | Issue: 10 | Pages: 1809-1818

10.1093/hmg/ddy094 | PMID 29547969 Get It

Association of Excessive Daytime Sleepiness With Longitudinal β-Amyloid Accumulation in Elderly Persons Without Dementia
Carvalho, Diego Z. , Louis, Erik K. St. , Lowe, Val J. , Roberts, Rosebud O., Przybelski, Scott A. , Petersen, Ronald C. , Jack, Clifford R. , Vemuri, Prashanthi , St Louis, Erik K, Jack, Clifford R , St Louis, E K , Vemuri, Prashanthi , Knopman, David S. , Boeve, Bradley F. , Mielke, Michelle M. , Machulda, Mary M. , Carvalho, Diego Z

JAMA Neurology | March 12, 2018 | Volume: 75 | Issue: 6 | Pages: 672

10.1001/jamaneurol.2018.0049 | PMID 29532057 Get It